Journal
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Volume 314, Issue 3, Pages 1370-1377Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/jpet.105.087023
Keywords
-
Categories
Ask authors/readers for more resources
Animal peptide toxins have become powerful tools to study structure-function relationships and physiological roles of voltage-activated Ca2+ channels. In the present study, we investigated the effects of PnTx3-6, a neurotoxin purified from the venom of the spider Phoneutria nigriventer on cloned mammalian Ca2+ channels expressed in human embryonic kidney 293 cells and endogenous Ca2+ channels in N18 neuroblastoma cells. Whole-cell patch-clamp measurements indicate that PnTx3-6 reversibly inhibited L-(alpha(1C)/Ca(v)1.2), N-(alpha(1B)/Ca(v)2.2), P/Q-(alpha(1A)/Ca(v)2.1), and R-(alpha(1E)/Ca(v)2.3) type channels with varying potency (alpha(1B) > alpha(1E) > alpha(1A) > alpha(1C)) and IC50 values of 122, 136, 263, and 607 nM, respectively. Inhibition occurred without alteration of the kinetics or the voltage dependence of the exogenously expressed Ca2+ channels. In N18 cells, PnTx3-6 exhibited highest potency against N- type (conotoxin-GVIA-sensitive) current. In contrast to its effects on high voltage-activated Ca2+ channels subtypes, application of 1 mu M PnTx3-6 did not affect alpha(1G)/Ca(v)3.1 T-type Ca2+ channels. Based on our study, we suggest that PnTx3-6 acts as a omega-toxin that targets high voltage-activated Ca2+ channels, with a preference for the Ca(v)2 subfamily (N-, P/Q-, and R-types).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available